Strattera - Official Site
Strattera - Official Site
Attention deficit/hyperactivity disorder (ADHD) impacts both children and adults. Learn about the symptoms and ADHD treatment from Strattera.

There are no adequate and well-controlled studies examining sexual dysfunction with STRATTERA treatment. A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator administered and scored. STRATTERA did not worsen anxiety in these patients as determined by the Pediatric Anxiety Rating Scale (PARS). Because of probable underreporting, it is impossible to provide an accurate estimate of the true incidence of these reactions.

People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs). Such symptoms should be reported to the patient’s prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Prompt medical attention is required in the event of suspected priapism. The following symptoms have been reported with STRATTERA: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness,. In the clinical development program, seizures were reported on 0.

You or your child/teenager should also not take an MAOI within 14 days of stopping Strattera. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. Patients should be instructed to contact their physician immediately should they develop pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained “flu-like” symptoms [see Patients should be instructed to call their doctor as soon as possible should they notice an increase in aggression or hostility. Rare postmarketing cases of priapism, defined as painful and nonpainful penile erection lasting more than 4 hours, have been reported for pediatric and adult patients treated with STRATTERA. The safety, efficacy and pharmacokinetics of STRATTERA in geriatric patients have not been evaluated. In short-term child and adolescent registration studies, 1. With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including , autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to. Mood swings didn’t meet the statistical significance on Breslow-Day test at 0. W hether any of the symptoms described above represent such a conversion is unknown. Pooled analyses of short-term (6 to 18 weeks) placebo-controlled trials of STRATTERA in children and adolescents (a total of 12 trials involving over 2200 patients, including 11 trials in ADHD and 1 trial in enuresis) have revealed a greater risk of suicidal ideation early during treatment in those receiving STRATTERA compared to placebo.

Strattera: Uses, Dosage, Side Effects -
Strattera is used to treat attention deficit hyperactivity disorder. Learn about side effects, interactions and indications. Strattera medication generic name Strattera (Atomoxetine HCl): Side Effects, Interactions ...Learn about Strattera (Atomoxetine HCl) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.

Talk to your healthcare provider if your child experiences slowing of growth (height and weight). The following reactions were reported by at least 2% of patients treated with atomoxetine, and equal to or less than placebo: pharyngolaryngeal pain, insomnia (insomnia includes the terms, insomnia, initial insomnia, middle insomnia). The highest dose used in rats is approximately 8 and 5 times the maximum human dose in children and adults, respectively, on a mg/m basis. Urinary hesitation includes the terms: urinary hesitation, urine flow decreased. Coadministration of STRATTERA with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary [see The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated.

Patients who develop symptoms such as exertional chest pain, unexplained , or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation. There was no evidence of symptom rebound or adverse reactions suggesting a drug-discontinuation or withdrawal syndrome. Thus, patients being treated with STRATTERA should be observed for the emergence of such symptoms. In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6-to 8-fold and Css, max is about 3-to 4-fold greater than atomoxetine alone. Following a 2-week double-blind placebo lead-in, STRATTERA was initiated at 0.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Be careful until you know how Strattera affects you or your child/teenager. The decreased pup survival was also seen at 25 mg/kg (but not at 13 mg/kg). There have also been reports of stroke and heart attack in adults, and increased blood pressure and heart rate. Call your doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Strattera. Approximately one-third of the patients met criteria for inattentive subtype and two-thirds met criteria for both inattentive and hyperactive/impulsive subtypes. STRATTERA should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate [see and blood pressure should be measured at baseline, following STRATTERA dose increases, and periodically while on therapy to detect possible clinically important increases. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Constipation didn’t meet the statistical significance on Breslow-Day test but is included in the table because of pharmacologic plausibility. Strattera can cause liver injury in some patients.